4.6 Article

Recommendations for Successful Training on Methods of Delivery of Biologics for Cardiac Regeneration A Report of the International Society for Cardiovascular Translational Research

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 3, 期 3, 页码 265-275

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2009.12.013

关键词

myocardial regeneration; stem cells; training; injection; catheter

资金

  1. Cardiovascular Biotherapeutics
  2. Angioblast Systems, Inc.
  3. Biologics Delivery Systems, Inc. (Cordis Corporation)
  4. Cardio3 Biosciences
  5. CardioPolymers Inc.
  6. Medtronic, Inc.
  7. Ablation Frontiers Inc.
  8. Astra-Zeneca Inc.
  9. Sanofi Aventis Inc.
  10. Magnetecs Inc.
  11. Bard Inc.
  12. Bioheart Inc.
  13. Lantheus
  14. Acusphere
  15. CV Therapeutics
  16. Philips Medical Systems
  17. General Electric Medical Systems
  18. Thoratec Corp
  19. Cordis Corporation
  20. Abbott Vascular
  21. Boston Scientific
  22. Cordis
  23. ev3
  24. [NIH-R01HL081715A1]
  25. [NIH-1R21DK078029-01]
  26. British Heart Foundation [RG/10/11/28457] Funding Source: researchfish

向作者/读者索取更多资源

The field of myocardial regeneration (angiogenesis and myogenesis) might prove to play an important role in the future management of cardiovascular disease. Stem cells are currently undergoing testing in Phase I and Phase II clinical trials. Methods of delivery will affect the outcome of such therapies, perhaps significantly. This document provides suggested guidance in 4 methods of delivery: endocardial, intracoronary, coronary sinus, and epicardial. (J Am Coll Cardiol Inty 2010;3:265-75) (C) 2010 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据